Accelerated Approval of Hiberix to Help Sustain Adequate Vaccine Supply
Accelerated Approval of Hiberix to Help Sustain Adequate Vaccine Supply
The U.S. Food and Drug Administration today approved Hiberix, a Haemophilus influenzae Type b (Hib) vaccine, as a booster dose for children 15 months through 4 years old. Hiberix is manufactured by GlaxoSmithKline, with U.S. headquarters in Research Triangle Park, N.C. and Philadelphia.